Functional delivery of xenogeneic p53 via extracellular vesicles induces apoptosis in human cancer cells
Main Article Content
Abstract
TP53 (encoding for the p53 tumor suppressor protein) is the most frequently mutated or deleted gene in human cancers, undermining p53's critical role in regulating cell cycle arrest and apoptosis. Here, we present a novel p53 replacement strategy using extracellular vesicles derived from chicken corneal epithelial cells, which naturally express high levels of cytoplasmic wild type p53. We demonstrate that corneal epithelium cells-derived extracellular vesicles encapsulate xenogeneic p53 and are readily internalized by human cancer cells, including those with mutant or null p53 backgrounds. Upon uptake, extracellular vesicles-delivered p53 translocates to the nucleus and activates canonical p53-dependent apoptotic pathways, evidenced by transcriptional upregulation of target genes such as p21, BAX, and PIDD, and induction of apoptosis across a range of human cancer cell lines. Proteomic and phosphoproteomic analyses of extracellular vesicles’ cargo revealed enrichment of apoptotic regulators and phosphorylated p53-associated proteins. In addition, p53-containing vesicles exhibited minimal cytotoxicity in primary human fibroblasts and human peripheral blood mononuclear cells, suggesting a selective anti-tumor activity. We also show that pre-treatment with chemotherapeutic agents sensitized cancer cells to vesicles-delivered p53, manifested by enhanced apoptosis. This study introduces an extracellular vesicles-based approach for functional p53 replacement, offering a promising therapeutic platform for targeting tumors with p53 loss or mutation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Zhang, C. et al. Gain-of-function mutant p53 in cancer progression and therapy. Journal of Molecular Cell Biology 12, 674–687 (2020).
3. Roszkowska, K. A., Piecuch, A., Sady, M., Gajewski, Z. & Flis, S. Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches. IJMS 23, 13287 (2022).
4. Gencel-Augusto, J. & Lozano, G. p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev. 34, 1128–1146 (2020).
5. Willis, A., Jung, E. J., Wakefield, T. & Chen, X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330–2338 (2004).
6. Patel, K. R. & Patel, H. D. p53: An Attractive Therapeutic Target for Cancer. CMC 27, 3706–3734 (2020).
7. Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting p53 pathways: mechanisms, structures and advances in therapy. Sig Transduct Target Ther 8, 92 (2023).
8. Hong, B., Heuvel, A., Prabhu, V., Zhang, S. & El-Deiry, W. Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities. CDT 15, 80–89 (2014).
9. Restoration of Wild‐Type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy. in Advances in Cancer Research 321–338 (Elsevier, 2007). doi:10.1016/s0065-230x(06)97014-6.
10. Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov 22, 127–144 (2023).
11. Saxena, M., Van Der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat Rev Cancer 21, 360–378 (2021).
12. Yang, Z., Sun, J. K.-L., Lee, M. M. & Chan, M. K. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. J Immunother Cancer 10, e005068 (2022).
13. Hu, J. et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14, 157 (2021).
14. Peng, Y., Bai, J., Li, W., Su, Z. & Cheng, X. Advancements in p53-Based Anti-Tumor Gene Therapy Research. Molecules 29, 5315 (2024).
15. Tendler, Y., Panshin, A., Weisinger, G. & Zinder, O. Identification of cytoplasmic p53 protein in corneal epithelium of vertebrates. Experimental Eye Research 82, 674–681 (2006).
16. Tendler, Y. & Panshin, A. Features of p53 protein distribution in the corneal epithelium and corneal tear film. Sci Rep 10, (2020).
17. Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).
18. Daguenet, E. et al. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 123, 339–348 (2020).
19. Pavlakis, E., Neumann, M. & Stiewe, T. Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis. IJMS 21, 9648 (2020).
20. Daguenet, E. et al. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 123, 339–348 (2020).
21. Lespagnol, A. et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap 3-null mice. Cell Death Differ 15, 1723–1733 (2008).
22. Watanabe, M., Hathcock, K., Vacchio, M., Moon, K. & Hodes, R. The role of p53 in antigen-specific and bystander T cell proliferative responses (50.15). The Journal of Immunology 184, 50.15-50.15 (2010).
23. Wang, R., Zhou, T., Liu, W. & Zuo, L. Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy. Oncotarget 9, 18637–18647 (2018).
24. Kim, C.-W. et al. Immortalization of human corneal epithelial cells using simian virus 40 large T antigen and cell characterization. Journal of Pharmacological and Toxicological Methods 78, 52–57 (2016).
25. Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P. & Kumar, S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. JEP Volume 13, 303–328 (2021).
26. Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C. & Lahav, G. Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing. Cell 165, 631–642 (2016).
27. Amit, M. et al. Human Feeder Layers for Human Embryonic Stem Cells1. Biology of Reproduction 68, 2150–2156 (2003).
28. Almazov, V. P. et al. [No title found]. Molecular Biology 36, 522–527 (2002).
29. Busuttil, R. A., Rubio, M., Dollé, M. E. T., Campisi, J. & Vijg, J. Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. Aging Cell 2, 287–294 (2003).
30. Zhang, L. et al. Analysis of Somatic Mutations in Senescent Cells Using Single-Cell Whole-Genome Sequencing. AgingBio 1, 20230005 (2023).